

## Contents

**Advisory Board Members** *xi*

**Preface** *xiii*

### **Part I General Aspects 1**

<b>1</b>	<b>Trends in Peptide Therapeutics</b>	<b>3</b>
	<i>Florence M. Brunel, Fa Liu, and John P. Mayer</i>	
1.1	Introduction	3
1.2	Peptides in Metabolic Diseases	4
1.2.1	Insulins	4
1.2.2	Glucagon-like Peptide-1	6
1.2.3	Glucagon	8
1.2.4	Combination Therapies	8
1.3	Peptide Antibiotics	9
1.3.1	Non-ribosomally Synthesized	9
1.3.2	Ribosomally Synthesized	11
1.4	Peptides in Cancer	12
1.4.1	Luteinizing Hormone Releasing Hormone	12
1.4.2	Somatostatin	13
1.4.3	Peptide–Drug Conjugates	14
1.4.4	Cancer Vaccines	15
1.5	Peptides in Bone Diseases	16
1.5.1	Calcitonin	16
1.5.2	Parathyroid Hormone (PTH) (1–34) and (1–84)	17
1.5.3	Parathyroid Hormone Related Protein	18
1.5.4	Incretin Peptides	19
1.5.5	Bone Morphogenic Protein-Derived Peptides	19
1.6	Peptides in Gastrointestinal Diseases	19
1.6.1	Glucagon-like Peptide-2	19
1.6.2	Guanylate Cyclase-C Agonists	20
1.7	Emerging Trends in Peptide Drug Discovery	22
1.7.1	Cell-Penetrating Peptides	22
1.7.2	Macrocyclic Peptides	23
1.8	Summary	23

	Acknowledgment	24
	List of Abbreviations	24
	References	25
	Biographies	34
<b>2</b>	<b>Physicochemical Parameters of Recently Approved Oral Drugs</b>	<b>35</b>
	<i>Andreas Ritzén and Laurent David</i>	
2.1	Introduction	35
2.2	FDA-Approved Drugs 2007–2017	36
2.2.1	Conclusions	40
2.3	Polar Surface Area in bRo5 Territory	42
2.3.1	Finding Chameleons with Molecular Dynamics	44
2.3.2	Conclusions	48
2.3.3	Methods	49
	List of Abbreviations	50
	References	51
	Biographies	52
	<b>Part II Drug Class Studies</b>	<b>55</b>
<b>3</b>	<b>Antibody–Drug Conjugates: Empowering Antibodies for the Fight Against Cancer</b>	<b>57</b>
	<i>Caroline Denevault-Sabourin, Francesca Bryden, Marie-Claude Viaud-Massuard, and Nicolas Joubert</i>	
3.1	Introduction	57
3.2	First Generation ADCs	58
3.2.1	Molecular Design	58
3.2.2	Mechanism of Action	60
3.2.3	Therapeutic Applications	60
3.2.4	Adverse Effects	60
3.3	Second Generation ADCs	62
3.3.1	Molecular Design	62
3.3.2	Mechanism of Action	63
3.3.3	Therapeutic Applications	67
3.3.4	Adverse Effects	67
3.4	Toward Next Generation ADCs	68
3.4.1	Site-Specific ADCs	69
3.4.2	New Formats of Immunoconjugates	70
3.4.3	ADC with New Payloads	74
3.5	Summary	76
	List of Abbreviations	76
	References	77
	Biographies	81

<b>4</b>	<b>Dopamine D<sub>2</sub> Partial Agonists – Discovery, Evolution, and Therapeutic Potential</b>	<b>83</b>
	<i>Marlene Jacobson, Wayne Childers, and Magid Abou-Gharbia</i>	
4.1	Introduction	83
4.2	Dopamine and Dopamine Receptors	83
4.2.1	Functional Selectivity and Biased Ligand Signaling	86
4.3	Schizophrenia and Earlier Antipsychotic Agents	86
4.4	Dopamine Partial Agonism	88
4.5	D <sub>2</sub> Partial Agonists	89
4.5.1	Dopamine-like Scaffolds – The “Classical” Pharmacophore	89
4.5.2	Non-dopamine-like Scaffolds – The “Nonclassical” Pharmacophore	91
4.5.3	Compounds Related to Bifeprunox	92
4.5.4	Methylaminochroman Scaffold – Aplindore	94
4.5.5	D <sub>2</sub> Partial Agonist Drug Discovery in the Wake of the Marketed Drugs	95
4.5.5.1	D <sub>2</sub> Partial Agonists Discovered Using Traditional D <sub>2</sub> Functional Screening	96
4.5.5.2	Bivalent Ligands	98
4.5.5.3	β-Arrestin-Biased D <sub>2</sub> Partial Agonists	98
4.5.5.4	G-protein-Biased D <sub>2</sub> Partial Agonists	99
4.5.6	Arylpiperazines and the Discovery of Aripiprazole and Brexpiprazole	101
4.5.7	The Road Leading to Cariprazine	102
4.6	Marketed D <sub>2</sub> Partial Agonist Antipsychotics	103
4.6.1	Aripiprazole (Abilify <sup>®</sup> )	104
4.6.1.1	History	105
4.6.1.2	Synthesis	105
4.6.1.3	Drug Substance	105
4.6.1.4	Pharmacology	105
4.6.1.5	Functional Selectivity and Biased Ligand Signaling	107
4.6.1.6	Pharmacokinetics and Metabolism	107
4.6.1.7	Clinical Data	107
4.6.2	Brexpiprazole (Rexulti <sup>®</sup> )	108
4.6.2.1	History	108
4.6.2.2	Synthesis	108
4.6.2.3	Drug Substance	109
4.6.2.4	Pharmacology	109
4.6.2.5	Functional Selectivity and Biased Ligand Signaling	110
4.6.2.6	Pharmacokinetics and Metabolism	110
4.6.2.7	Clinical Data	110
4.6.3	Cariprazine (Vraylar <sup>®</sup> )	111
4.6.3.1	History	111
4.6.3.2	Synthesis	112

- 4.6.3.3 Drug Substance 112
- 4.6.3.4 Pharmacology 112
- 4.6.3.5 Functional Selectivity and Biased Ligand Signaling 113
- 4.6.3.6 Pharmacokinetics 113
- 4.6.3.7 Clinical Data 114
- 4.7 Conclusions 115
- List of Abbreviations 116
- References 117
- Biographies 129

### Part III Case Studies 131

- 5 Discovery of Etelcalcetide for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease 133**  
*Amos Baruch and Derek Maclean*
  - 5.1 Introduction 133
  - 5.2 Compound Design and Structure–Activity Relationships 135
    - 5.2.1 Optimization of the Cationic Charge 135
    - 5.2.2 Alanine Scan of dCR<sub>6</sub> 136
    - 5.2.3 Double Alanine Scan of dCR<sub>6</sub> 138
    - 5.2.4 SAR of Alanine Residues in Ac-carrarar-NH<sub>2</sub> and Ac-crrrarar-NH<sub>2</sub> 138
    - 5.2.5 Importance of the Thiol Residue 140
    - 5.2.6 Thiol Conjugates – Selection of Etelcalcetide 140
  - 5.3 Preclinical Studies 141
  - 5.4 Mechanism of Action of Etelcalcetide 144
  - 5.5 Clinical Studies 145
  - 5.6 Summary 149
    - Acknowledgments 149
    - List of Abbreviations 149
    - References 150
    - Biographies 153
- 6 Development of Lenvatinib Mesylate, an Angiogenesis Inhibitor Targeting VEGF and FGF Receptors 155**  
*Akihiko Tsuruoka, Yasuhiro Funahashi, Junji Matsui, and Tomohiro Matsushima*
  - 6.1 Introduction 155
  - 6.2 Recent Progress in the Development of Molecular Targeted Anticancer Agents 155
  - 6.3 Tumor Angiogenesis 156
  - 6.4 Development of Resistance to VEGF-Targeting Drugs 156
  - 6.5 Discovery of Lenvatinib, a Drug Targeting VEGFR and FGFR 157
  - 6.6 Inhibition of Kinase Activity by Lenvatinib and Discovery of the Novel Type V Kinase-Binding Mode 158

- 6.7 Antitumor Effects of Lenvatinib in Human Thyroid Cancer Cell Lines 161
- 6.8 Antitumor Effects of Lenvatinib in Human Renal Cell Cancer Cell Lines and Its Mechanism of Action 162
- 6.9 Conclusions and Perspectives 162
  - List of Abbreviations 163
  - References 164
  - Biographies 167
  
- 7 Ocrelizumab: A New Generation of anti CD20 mAb for Treatment of Multiple Sclerosis 169**  
*Andrew C. Chan, Paul Brunetta, and Peter Chin*
  - 7.1 Introduction: B Cells Play Critical Roles in Immunity 169
  - 7.2 Role of B Cells in Autoimmunity 172
  - 7.3 CD20-Targeting Therapeutic Antibodies 173
  - 7.4 Rituximab: the First Anti-CD20 mAb Experience in Autoimmunity 176
  - 7.5 Effects of Rituximab on Antibodies and Autoantibodies 178
  - 7.6 Rituximab in AAV and Other Autoimmune Disorders 178
  - 7.7 Beginnings of Ocrelizumab 179
  - 7.8 Multiple Sclerosis 180
  - 7.9 Multiple Sclerosis Disease Pathogenesis 181
  - 7.10 Rituximab: The First Anti-CD20 mAb Experience in Multiple Sclerosis 183
    - 7.10.1 HERMES Junior 183
    - 7.10.2 HERMES 183
    - 7.10.3 OLYMPUS 184
  - 7.11 Ocrelizumab in Multiple Sclerosis 184
    - 7.11.1 OPERA 185
    - 7.11.2 ORATORIO 186
  - 7.12 The Conundrum of B Cells in Multiple Sclerosis 187
  - 7.13 Final Comments 187
    - List of Abbreviations 188
    - Acknowledgments 189
    - References 189
    - Biographies 198
  
- 8 The Story of Rucaparib (Rubraca) 201**  
*Bernard T. Golding*
  - 8.1 Introduction 201
  - 8.2 Benzoxazole-/Benzimidazole-carboxamides and Quinazolinones 205
  - 8.3 The Road to Rucaparib/Rubraca 212
  - 8.4 The Emergence of Single-Agent Therapy 216
  - 8.5 Clinical Studies 217

8.6	Conclusion	218
	Acknowledgments	218
	References	219
	Biography	223
<b>9</b>	<b>Discovery and Development of Venetoclax, a Selective Antagonist of BCL 2</b>	<b>225</b>
	<i>Wayne J. Fairbrother, Joel D. Levenson, Deepak Sampath, and Andrew J. Souers</i>	
9.1	Introduction	225
9.2	Discovery of Venetoclax – Structure-Based Design	227
9.3	Preclinical Studies	232
9.3.1	Mechanism of Action	232
9.3.2	Predictive Biomarkers of Venetoclax Sensitivity	233
9.3.3	Efficacy of Venetoclax as Monotherapy and in Combination with Targeted Agents or Chemotherapeutics	234
9.4	Clinical Studies	236
	List of Abbreviations	238
	References	239
	Biographies	244
	<b>Index</b>	<b>247</b>